One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
The Annual Meeting of Shareholders will take place April 22, 2010, at the Hyatt Regency New Brunswick, 2 Albany Street, New Brunswick, New Jersey. The meeting will convene at 10 a.m. All shareholders are cordially invited to attend. A formal Notice of Meeting, Proxy Statement and Proxy have been sent to shareholders.
Copies of the Company’s 2009 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to the Securities and Exchange Commission, Proxy Statement, and this Annual Report are available online at www.investor.jnj.com/sec-filings.cfm, or to shareholders without charge upon written request to the Secretary at the Company’s principal address or by calling (800) 950‑5089.
In addition, on the Company’s Corporate Governance web site at www.investor.jnj.com/governance.cfm, shareholders can view the Company’s Principles of Corporate Governance, Charters of the Audit Committee, Compensation & Benefits Committee and Nominating & Corporate Governance Committee, Policy on Business Conduct for Employees and Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers. Copies of these documents are available to shareholders without charge upon written request to the Secretary at the Company’s principal address. The Company is required to file as an Exhibit to its Form 10-K for each fiscal year certifications under Section 302 of the Sarbanes-Oxley Act signed by the Chief Executive Officer and the Chief Financial Officer. In addition, the Company is required to submit a certification signed by the Chief Executive Officer to the New York Stock Exchange within 30 days following the Annual Meeting of Shareholders. Copies of the certifications filed for previous years are posted on the Company’s Corporate Governance web site, and future certifications will be posted promptly upon filing.
Listed on New York Stock Exchange
Stock Symbol JNJ
Shareholder Relations Contact
Steven M. Rosenberg
Investor Relations Contact
Vice President, Investor Relations
Transfer Agent and Registrar
Questions regarding stock holdings, certificate replacement/transfer, dividends and address changes should be directed to:
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
(800) 328-9033 or
(781) 575-2718 (outside the U.S.)
Dividend Reinvestment Plan
The Plan allows for full or partial dividend reinvestment, and additional monthly cash investments up to $50,000 per year, in Johnson & Johnson common stock without brokerage commissions or service charges on stock purchases. If you are interested in participating in the Plan and need an authorization form and/or more information, please call Computershare Trust Company, N.A. at (800) 328‑9033 or (781) 575‑2718 (outside the U.S.).
Shareholders who have inquiries regarding stock-related matters can communicate directly with Computershare Trust Company, N.A. via a telecommunications device (TDD). The telephone number for this service is (800) 952‑9245 or (781) 575‑2692 (outside the U.S.).
Registered shareholders who wish to receive electronic notice of online access to future annual reports and proxy materials instead of paper copies may register online: www.computershare‑na.com/green
Beneficial Johnson & Johnson shareholders (you own shares through a broker or bank) can register for online delivery of materials by going to: enroll.icsdelivery.com/jnj
Johnson & Johnson on the Web
Company website: www.jnj.com
Company blog: www.jnjbtw.com
Johnson & Johnson history blog: www.kilmerhouse.com
Facebook: Follow the Johnson & Johnson Network
The following trademarks and trade names of Johnson & Johnson and its affiliated companies appear in this report:
1-DAY ACUVUE TRUEYE, ACCLARENT, ACIPHEX/PARIET, ACTIVE NATURALS, ACTIVE NATURALS INSTITUTE, ACTIVE PHOTOBARRIER COMPLEX, ACUVUE TRUEYE, AVEENO, BIOSENSE WEBSTER, BX VELOCITY, CARTO, CELLSEARCH, CENTOCOR ORTHO BIOTECH, CENTOCOR RESEARCH & DEVELOPMENT, CHARITÉ, CLEAN & CLEAR, CONCERTA, CORDIS, COUGAR BIOTECHNOLOGY, CYPHER, DEPUY, DEPUY INSTITUTE, DEPUY ORTHOPAEDICS, DABAO, DIABETES CARE INSTITUTE, DURAGESIC, EARTHWARDS, ENSEAL, ETHICON, ETHICON ENDO-SURGERY, EVICEL, FEVERFEW PFE, FINSBURY ORTHOPAEDICS, FLEX HD, GLOSTER EUROPE, HARMONIC, HELIOPLEX, INTELENCE, INVEGA, INVEGA SUSTENNA, JANSSEN ALZHEIMER IMMUNOTHERAPY, JANSSEN-CILAG, JOHNSON & JOHNSON, JOHNSON & JOHNSON CONSUMER GROUP OF COMPANIES, JOHNSON & JOHNSON DIABETES INSTITUTE, JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, JOHNSON’S, LE PETIT MARSEILLAIS, LEVAQUIN/FLOXIN, LIFESCAN, LISTERINE, MCNEIL NUTRITIONALS, MEMORYGEL, MENTOR, NATRECOR, NEUTROGENA, NUCYNTA, OASYS, ORTHO-CLINICAL DIAGNOSTICS, ORTHO EVRA, ORTHO TRI-CYCLEN LO, PINNACLE COMPLETE, PREZISTA, PRILIGY, PROCRIT/EPREX, PROPULSID, QUIXIL, RAZADYNE, REACH, REALIZE, REMICADE, REOPRO, RISPERDAL, RISPERDAL CONSTA, ROC, SEDASYS, SILENT, SIMPONI, SKIN ID, SPLENDA, STELARA, SUN CRYSTALS, SURGIFLO, TIBOTEC, TIBOTEC PHARMACEUTICALS, TIBOTEC-VIRCO VIROLOGY BVBA, TOPAMAX, TRU-VU, ULTRAM ER, VANIA EXPANSION, VERIDEX, THE VISION CARE INSTITUTE, XIAN-JANSSEN PHARMACEUTICAL
The following trademarks and trade names of other companies also appear in this report:
Academy for Educational Development, American Academy of Dermatology, American Society of Plastic Surgeons, Bayer HealthCare AG (rivaroxaban), Children Without Worms, Cleveland Clinic, Crucell, Elan, Forest Stewardship Council, Gilead Sciences, Global Alliance for TB Drug Development, Good Housekeeping, Grünenthal, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Merck & Co., Mitsubishi Tanabe Pharma, National Children’s Oral Health Foundation, Pfizer, Prix Galien, Royal Marsden Hospital, Siemens Healthcare Diagnostics, Task Force for Global Health, TerraCycle, Tianjin Medical University Cancer Hospital, U.S. Agency for International Development, U.S. Food and Drug Administration, Velcade (Millennium: The Takeda Oncology Company), World Wildlife Fund